Skip to content

ImmunityBio, Inc. IBRX Finance Lease Liability - Undiscounted Excess Amount

Finance Lease Liability - Undiscounted Excess Amount at other companies

Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s finance lease liability - undiscounted excess amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s finance lease liability - undiscounted excess amount?
ImmunityBio, Inc. (IBRX) reported finance lease liability - undiscounted excess amount of $64K in Q1 2026.
What does finance lease liability - undiscounted excess amount mean?
This represents the total undiscounted future cash payments required for finance leases, excluding the recognized lease liability. It provides visibility into the long-term contractual obligations for leased assets that are not yet reflected as current debt. Monitoring this helps investors understand the full scale of off-balance sheet or future lease commitments.